Daxor Corporation Announces That Baltimore VA Medical Center of Baltimore, MD Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY--(Marketwire - September 07, 2010) -

Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Baltimore VA Medical Center of Baltimore, Maryland. This will provide the Baltimore VA Medical Center with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient’s total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis.

The Baltimore VA Medical Center is one of the most modern health care facilities in the country, offering veterans state-of-the-art medical technology, clinical services and research programs. The Medical Center created the world’s first filmless radiology department, which gives health care providers almost instant access to patient radiology images from anywhere in the facility and throughout the health care system. The Baltimore VA Medical Center is the acute medical and surgical care facility for the VA Maryland Health Care System. It is located next to the University of Maryland Medical Center and shares staff, resources and technology with the University. The Baltimore VA Medical Center has one of the largest and best funded research and development programs in the entire VA system. It is currently conducting studies in a number of therapeutic areas. The Geriatric Research, Education and Clinical Center conducts research on prevention of stroke and cardiovascular disease through exercise and nutrition therapy in older veterans. It also offers one of only two Multiple Sclerosis (MS) Centers of Excellence in the VA System. In addition, it provides one of the VA’s eight Mental Illness Research, Education and Clinical Centers.

The Baltimore VA Medical Center will be participating in a multi-center clinical trial (TEAM-HF) which will test whether incorporation of blood volume assessments into treatment decisions can improve the care and outcomes of patients with heart failure. Dr. Stephen Gottlieb will serve as the local Principal Investigator, and will be joined by Dr. Shawn Robinson to conduct the study at the Baltimore VA Medical Center. The objective of the interventional TEAM-HF Study is to determine whether correcting any identified blood volume abnormalities in heart failure patients leads to decreased hospitalization and mortality, and an improvement in exercise capacity and quality of life. This trial will enroll 300 heart failure patients from 11 medical centers.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor’s single use diagnostic kit. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website at www.Daxor.com.